MOS
NTLA icon

MGO One Seven’s Intellia Therapeutics NTLA Stock Holding History

MGO One Seven’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-2,100
Closed -$28K – 1220
2018
Q4 		$28K Buy
+2,100
New +$39K 0.01% 800
2018
Q1 		$44K Hold
2,100
– – 0.02% 635
2017
Q4 		$40K Buy
+2,100
New +$48.5K 0.02% 676

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OTPPB
Ontario Teachers' Pension Plan Board Toronto, Ontario, Canada $3.46B AUM 7.79% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

MGO One Seven's NTLA Position: Q1 2019 in Review

MGO One Seven sold out of Intellia Therapeutics (NTLA) in Q1 2019, closing a stake of 2,100 shares — an estimated $28K sold.

MGO One Seven first reported a position in NTLA in Q4 2017 and held it in 3 quarters. The position peaked at $44K in Q1 2018. 148 funds tracked by Wall St. Rank hold NTLA as of Q1 2019.

  • MGO One Seven reported no remaining Intellia Therapeutics position as of Q1 2019 after selling out during the quarter.
  • MGO One Seven sold 2,100 Intellia Therapeutics shares in Q1 2019, an estimated $28K.
  • MGO One Seven first reported a position in Intellia Therapeutics in Q4 2017 and held it in 3 quarters.
  • MGO One Seven's Intellia Therapeutics position peaked at $44K in Q1 2018.
  • 148 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2019.

Based on MGO One Seven's 13F filing for Q1 2019, filed 9 Apr 2019.